Heartflow, Inc. HTFL
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- +94.07%
- 1 year
- +66.92%
- Market cap
- 4.92B
- Revenue (ttm)
- 212.07M
- Profit margin
- -55.82%
- EPS (ttm)
- -0.24
- Shares out
- 86.95M
- Forward P/E
- -208.88
- YTD return
- +94.07%
- 1-year return
- +66.92%
- Volume
- 1.52M
- Avg volume
- 1.95M
- Open
- 54.59
- Previous close
- 54.40
- Day's range
- 54.53 – 57.20
- 52-week range
- 20.13 – 60.56
- Analysts
- Strong Buy
- Price target
- 50.50 (-10.7%)
- Earnings date
- Nov 12, 2026
1D +2.17 (+3.99%)
Key statistics
- Enterprise value
- 4.59B
- PEG ratio
- 0.00
- Price / sales
- 23.19
- Price / book
- 17.54
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 47.60%
- Free cash flow
- -33.61M
- Total cash
- 162.55M
- Total debt
- 27.13M
- Return on equity
- -154.23%
- Short % of float
- 12.19%
- 50-day average
- 51.00
- 200-day average
- 34.29
Analyst view
Consensus: strong buy
- Target (low)
- 39.00
- Target (mean)
- 50.50
- Target (high)
- 64.00
- Strong buy2
- Buy6
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.10246.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.1029 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | -0.13369 | -0.07 | +0.06 | +47.64% |
| May 14, 2026 | Mar 31, 2026 | -0.18763 | -0.16 | +0.03 | +14.73% |
| Mar 18, 2026 | Dec 31, 2025 | -0.18763 | -0.12 | +0.07 | +36.04% |
| Nov 12, 2025 | Sep 30, 2025 | -0.20 | -0.27 | -0.07 | -35.00% |
| Sep 19, 2025 | Jun 30, 2025 | -0.21296 | -0.06 | +0.15 | +71.83% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Sep 22, 2026 | Canaccord Genuity | main | Buy | Buy |
| Sep 9, 2026 | UBS | init | — | Neutral |
| Aug 14, 2026 | Canaccord Genuity | main | Buy | Buy |
| Aug 14, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Aug 14, 2026 | Piper Sandler | reit | Overweight | Overweight |
About Heartflow, Inc.
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies. Its platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. HeartFlow, Inc. was formerly known as Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009. The company was incorporated in 2007 and is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- heartflow.com
News
Heartflow To Present DECIDE Registry Data Showing 34% Reduction In Major Cardiovascular Events With AI Plaque Analysis, At AHA Scientific Sessions 2026 
AHA 2026: Heartflow Plaque Analysis Associated with 34% Fewer Major CVD Events and Half the Rate of Heart Attack at One Year in Prospective DECIDE Registry 
TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients 
Elucid Bioimaging Says Co Is Aware Of A Lawsuit Filed By Heartflow, On October 22, 2026. Elucid Will Respond To And Defend Against The Claims In The Lawsuit Through The Appropriate Legal Channels 
Piper Sandler Reiterates Overweight on HeartFlow, Raises Price Target to $64 
10 Health Care Stocks With Whale Alerts In Today’s Session
Your note
Sign in to keep a note on HTFL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAIN CAPITAL LIFE SCIENCES INVESTORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Apr 29, 2026 | 0 |
| BARABE TIMOTHY CRAIG | Director | Conversion of Exercise of derivative security | Jul 21, 2026 | 188,231 |
| FARQUHAR JOHN C. M. | Chief Executive Officer | Sale | Oct 11, 2026 | 283,014 |
| HEALTHCOR PARTNERS MANAGEMENT L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 10, 2025 | 0 |
| JONES MARIE L | Officer | Stock Award(Grant) | Mar 5, 2026 | 32,176 |
| LIGHTCAP JEFFREY C | Director | Conversion of Exercise of derivative security | Jul 23, 2026 | 6,991,240 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 9.72% | 8,448,158 | 477.91M | Jun 29, 2026 |
| Wellington Management Group, LLP | 9.04% | 7,864,226 | 444.88M | Jun 29, 2026 |
| Blackrock Inc. | 5.98% | 5,197,747 | 294.04M | Jun 29, 2026 |
| FMR, LLC | 5.54% | 4,820,944 | 272.72M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.12% | 3,584,428 | 202.77M | Jun 29, 2026 |
| BAMCO Inc. | 3.71% | 3,225,133 | 182.45M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 6.67% | 5,795,579 | 327.86M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.84% | 2,467,177 | 139.57M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.29% | 1,987,442 | 112.43M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.05% | 1,781,440 | 100.78M | Jun 29, 2026 |
| BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd. | 1.85% | 1,604,894 | 90.79M | Jun 29, 2026 |
| AIM Counselor Series TRT -Invesco Discovery Fd. | 1.47% | 1,275,225 | 72.14M | Aug 30, 2026 |